Literature DB >> 11874415

Complete virilization in congenital adrenal hyperplasia: clinical course, medical management and disease-related complications.

J Woelfle1, W Hoepffner, W G Sippell, J H Brämswig, P Heidemann, D Deiss, A Bökenkamp, C Roth, U Irle, H A Wollmann, M Zachmann, K Kubini, N Albers.   

Abstract

OBJECTIVE: In girls with congenital adrenal hyperplasia (CAH), genital ambiguity usually leads to a rapid neonatal diagnosis. Rarely, CAH causes complete virilization and male sex assignment with a delayed diagnosis. After being confronted with very specific problems in two of such patients, we collected data of patients with CAH and complete virilization in a nationwide study to delineate specific problems of these rare patients in order to improve their management. DESIGN AND PATIENTS: Through the German Working Group of Paediatric Endocrinology (Arbeitsgemeinschaft Pädiatrische Endokrinologie, APE), questionnaires were sent to all members caring for patients with CAH and complete virilization in their endocrine clinics. Data from 16 patients from 10 paediatric endocrine centres were assessed by questionnaire.
RESULTS: The following problems have been encountered. (1) Sex assignment/gender identity: initially all patients had a male sex assignment. Six patients were diagnosed during the first month of life. Five were reassigned to female sex immediately, one at the age of 19 months. Except in one girl demonstrating some tomboyish behaviour, gender role behaviour in these patients did not differ from unaffected girls. Ten patients were diagnosed late at 3.4--7 years of age. In seven patients with a late diagnosis, male sex assignment was maintained; one of them expressed some concerns about living as a male. In three patients late sex reversal was performed, gender identity is very poor in one and new sex assignment is currently under consideration. (2) SURGERY: irrespective of the sex assigned, all patients had between one and three surgical procedures, including clitoris reduction and (repeated) vaginoplasties in patients with female sex assignment. Hysterectomy and ovarectomy were performed in patients with male sex assignment. (3) Short stature: patients with a late diagnosis of CAH had extremely advanced bone ages of +6.3 to +9.5 years, leading to severely reduced final height of 137 to 150 cm in adult patients. Patients tended to follow height percentiles of genetic females. One pubertal patient was suicidal due to short stature. (4) Central precocious puberty (CPP): prolonged exposition to adrenal androgens led to CPP in one patient. He was treated with GnRH analogues until gonadectomy.
CONCLUSIONS: Patients with CAH and complete virilization have a high risk of being diagnosed late. There are major problems and uncertainties of the patients' families and the treating physicians concerning gender assignment. Gender identity is disturbed in some patients. In addition, multiple surgical procedures are necessary and short stature as well as central precocious puberty might be important to avoid late sequelae. While some surgical interventions are probably unavoidable, most of these issues could be resolved with an early diagnosis. Thus, especially for these patients, a neonatal screening programme for CAH would be of paramount importance.

Entities:  

Mesh:

Year:  2002        PMID: 11874415     DOI: 10.1046/j.0300-0664.2001.01463.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Congenital adrenal hyperplasia: long-term evaluation of feminizing genitoplasty and psychosocial aspects.

Authors:  D K Gupta; Sharma Shilpa; A C Amini; M Gupta; Gautam Aggarwal; Gupta Deepika; Khatri Kamlesh
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

Review 2.  Management of Childhood Congenital Adrenal Hyperplasia-An Integrative Review of the Literature.

Authors:  Louise Fleming; Marcia Van Riper; Kathleen Knafl
Journal:  J Pediatr Health Care       Date:  2017-04-13       Impact factor: 1.812

Review 3.  Intersex and gender assignment; the third way?

Authors:  S F Ahmed; S Morrison; I A Hughes
Journal:  Arch Dis Child       Date:  2004-09       Impact factor: 3.791

Review 4.  Gender dysphoria associated with disorders of sex development.

Authors:  Paulo Sampaio Furtado; Felipe Moraes; Renata Lago; Luciana Oliveira Barros; Maria Betânia Toralles; Ubirajara Barroso
Journal:  Nat Rev Urol       Date:  2012-10-09       Impact factor: 14.432

5.  False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasia.

Authors:  Felix Schreiner; Christoph Brack; Kirsten Salzgeber; Walburga Vorhoff; Joachim Woelfle; Bettina Gohlke
Journal:  Eur J Pediatr       Date:  2007-05-22       Impact factor: 3.183

6.  Clinical Characteristics of 46,XX Males with Congenital Adrenal Hyperplasia

Authors:  Şenay Savaş-Erdeve; Zehra Aycan; Semra Çetinkaya; Ayşe Pınar Öztürk; Firdevs Baş; Şükran Poyrazoğlu; Feyza Darendeliler; Elif Özsu; Zeynep Şıklar; Meliha Demiral; Edip Unal; Mehmet Nuri Özbek; Fatih Gürbüz; Bilgin Yüksel; Olcay Evliyaoğlu; Nesibe Akyürek; Merih Berberoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-12-30

7.  Congenital adrenal hyperplasia: classification of studies employing psychological endpoints.

Authors:  Stephanie A Stout; Margarita Litvak; Natashia M Robbins; David E Sandberg
Journal:  Int J Pediatr Endocrinol       Date:  2010-10-05

8.  Review of Outcome Information in 46,XX Patients with Congenital Adrenal Hyperplasia Assigned/Reared Male: What Does It Say about Gender Assignment?

Authors:  Peter A Lee; Christopher P Houk
Journal:  Int J Pediatr Endocrinol       Date:  2010-12-21

9.  Gender Dysphoria in 46,XX Persons with Adrenogenital Syndrome Raised as Females: An Addendum.

Authors:  Ricardo González; Barbara M Ludwikowski
Journal:  Front Pediatr       Date:  2015-01-06       Impact factor: 3.418

10.  Should CAH in Females Be Classified as DSD?

Authors:  Ricardo González; Barbara M Ludwikowski
Journal:  Front Pediatr       Date:  2016-05-13       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.